Broad Health Condition Anaesthesiology
Oral and Gastrointestinal
Specific Health ConditionPain management
Other mental health disorders
Other neurological disorders
Inflammatory bowel disease
Anticipated date of first participant enrolment20/07/2020
Anticipated date of last participant enrolment20/07/2020
This study is a multicenter, open label, longitudinal observational study aiming to assess the safety, tolerability and efficacy of MediCabilis™ when used at the prescribed dose by physicians for different indications using data reported by patients during treatment.
Key inclusion criteria
Participants will be any patient who has been prescribed MediCabilis through the Special Access Scheme B or by an authorised prescriber. Participants may be taking MediCabilis in any dose, form, duration and free quency, and for any condition. Patients of any gender who is equal or greater than 18 years may participate. Prospective patients that understand the informed consent process and to give informed consent to participate in the study. Diagnosis of their condition/disease confirmed by patient’s GP or specialist. Prospective participants agree to abstain from using illicit cannabis products for the duration of their participation in the study.
Minimum age18 Years
GenderBoth males and females
Key exclusion criteria
Any severe cognitive, intellectual disability, medical or psychiatric condition that impairs the participant’s ability to provide informed consent. Patients who are using illicit forms of cannabis.
Sponsor Primary Sponsor Type: Commercial sector/Industry
Primary Sponsor Name: Bod Australia
Primary Sponsor Address: Level 1, 377 New South Head Road DOUBLE BAY NSW 2028
Primary Sponsor Country: Australia
Contact person for information and recruitmentDr
Bod Australia Level 1, 377 New South Head Road Double Bay NSW 2038 NSW
+61 2 9199 5080